ANTONIO PINERO- PILONA
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
- Where
- HUDSON, FL
- NPI
- 1720082068
- Received
- $94,272 in 455 records, 2019 to 2025 ($68,850 general, $25,422 research)
- As principal investigator
- $1,971,911 of research payments to others in 96 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 36 | $1,132 |
| 2024 | General payment | 43 | $1,230 |
| 2023 | General payment | 50 | $4,542 |
| 2022 | General payment | 37 | $10,413 |
| 2022 | Research payment | 2 | $12,560 |
| 2021 | General payment | 23 | $8,293 |
| 2021 | Research payment | 1 | $48 |
| 2020 | General payment | 68 | $11,907 |
| 2020 | Research payment | 3 | $10,353 |
| 2019 | General payment | 190 | $31,330 |
| 2019 | Research payment | 2 | $2,459 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 35 | $45,986 |
| Research payment | 8 | $25,422 |
| Food and Beverage | 381 | $11,038 |
| Travel and Lodging | 23 | $8,774 |
| Consulting Fee | 1 | $2,925 |
| Education | 7 | $125 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-14 | Corcept Therapeutics | $13 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-29 | Lilly USA, LLC | $27 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-10-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-10-16 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-10-09 | Bayer Healthcare Pharmaceuticals Inc. | $27 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-03 | Abbott Laboratories | $22 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2025 | |
| 2025-09-30 | Medtronic, Inc. | $180 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2025 | |
| 2025-08-14 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-08-08 | BETA BIONICS, INC. | $19 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-10 | Chiesi USA, Inc. | $19 | Food and Beverage | Cash or cash equivalent | MYCAPSSA Drug, ACROMEGALY | 2025 | |
| 2025-07-09 | Soleno Therapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | VYKAT XR Drug, Prader-Willi syndrome | 2025 | |
| 2025-06-19 | Abbott Laboratories | $22 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2025 | |
| 2025-06-17 | Sandoz Inc. | $18 | Food and Beverage | In-kind items and services | HYRIMOZ Biological, Immunology | 2025 | |
| 2025-05-29 | Tandem Diabetes Care, Inc. | $107 | Food and Beverage | In-kind items and services | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-05-29 | Amneal Pharmaceuticals LLC | $15 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2025 | |
| 2025-05-21 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-05-14 | BETA BIONICS, INC. | $28 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-04-23 | Corcept Therapeutics | $24 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-04-17 | IBSA Pharma Inc. | $24 | Food and Beverage | Cash or cash equivalent | Tirosint Drug, Endocrinology | 2025 | |
| 2025-04-15 | SANOFI-AVENTIS U.S. LLC | $88 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2025 | |
| 2025-04-08 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-04-03 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-03-13 | Bayer Healthcare Pharmaceuticals Inc. | $29 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-02-27 | Insulet Corporation | $20 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2025 | |
| 2025-02-24 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-02-19 | Radius Health, Inc. | $86 | Food and Beverage | In-kind items and services | Tymlos Drug, Endocrinology | 2025 | |
| 2025-02-11 | Insulet Corporation | $22 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2025 | |
| 2025-02-06 | Bayer Healthcare Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-02-05 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-01-23 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-01-22 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-01-16 | Insulet Corporation | $26 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2025 | |
| 2025-01-09 | Corcept Therapeutics | $24 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2024-12-20 | IBSA Pharma Inc. | $22 | Food and Beverage | Cash or cash equivalent | Tirosint Drug, Endocrinology | 2024 | |
| 2024-12-18 | Corcept Therapeutics | $101 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2024 | |
| 2024-12-12 | Esperion Therapeutics, Inc. | $70 | Food and Beverage | In-kind items and services | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2024 | |
| 2024-12-11 | Corcept Therapeutics | $8 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2024 | |
| 2024-12-05 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-11-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2024 | |
| 2024-10-18 | Corcept Therapeutics | $11 | Education | In-kind items and services | Korlym Drug, Endocrinology | 2024 | |
| 2024-10-17 | Bayer Healthcare Pharmaceuticals Inc. | $10 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-10-04 | Bayer Healthcare Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-09-26 | Medtronic, Inc. | $21 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2024 | |
| 2024-09-18 | SANOFI-AVENTIS U.S. LLC | $97 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2024 | |
| 2024-09-18 | BETA BIONICS, INC. | $23 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2024 | |
| 2024-09-12 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-09-11 | Bayer Healthcare Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-09-10 | Medtronic, Inc. | $13 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2024 | |
| 2024-09-10 | Corcept Therapeutics | $8 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2024 | |
| 2024-08-09 | Alnylam Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | GIVLAARI Drug, Genetic Disease | 2024 | |
| 2024-08-07 | Medtronic, Inc. | $109 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2024 | |
| 2024-06-27 | Lexicon Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-12 | BETA BIONICS, INC. | $21 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2024 | |
| 2024-06-11 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-06-05 | Medtronic, Inc. | $18 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2024 | |
| 2024-05-30 | RECORDATI_RARE_DISEASES_INC. | $22 | Food and Beverage | In-kind items and services | SIGNIFOR LAR Drug, ENDOCRINE AGENT | 2024 | |
| 2024-05-29 | Corcept Therapeutics | $9 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2024 | |
| 2024-05-23 | Corcept Therapeutics | $9 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2024 | |
| 2024-05-14 | Corcept Therapeutics | $21 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2024 | |
| 2024-05-14 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | SOMAVERT Drug, ENDOCRINE DISEASE;METABOLIC DISEASE | 2024 | |
| 2024-05-09 | Bayer Healthcare Pharmaceuticals Inc. | $28 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-05-08 | BETA BIONICS, INC. | $29 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2024 | |
| 2024-04-25 | Corcept Therapeutics | $25 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2024 | |
| 2024-04-12 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2024 | |
| 2024-04-05 | Corcept Therapeutics | $24 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2024 | |
| 2024-03-22 | IBSA Pharma Inc. | $22 | Food and Beverage | Cash or cash equivalent | Tirosint Drug, Endocrinology | 2024 | |
| 2024-03-07 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-03-07 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2024 | |
| 2024-03-05 | Dexcom, Inc. | $76 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2024 | |
| 2024-02-28 | Astellas Pharma US Inc | $28 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2024 | |
| 2024-02-22 | SANOFI-AVENTIS U.S. LLC | $81 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2024 | |
| 2024-02-21 | Abbott Laboratories | $18 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2024 | |
| 2024-02-13 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2024 | |
| 2024-02-08 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2024-01-19 | Nevro Corp. | $15 | Food and Beverage | In-kind items and services | Senza Device, Spinal Cord Stimulator | 2024 | |
| 2024-01-03 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2023-12-20 | Corcept Therapeutics | $23 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-12-14 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2023 | |
| 2023-11-30 | Lexicon Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | Inpefa Drug, Inhibitor of SGLT2 and SGLT1 | 2023 | |
| 2023-11-14 | Dexcom, Inc. | $13 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-10-25 | Xeris Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2023 | |
| 2023-10-18 | SANOFI-AVENTIS U.S. LLC | $123 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-03 | Dexcom, Inc. | $14 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-09-21 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-09-20 | Amgen Inc. | $119 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2023 | |
| 2023-09-19 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-09-08 | Corcept Therapeutics | $22 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-09-07 | Bayer Healthcare Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-09-05 | Lilly USA, LLC | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-09-01 | Dexcom, Inc. | $23 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-08-31 | Astellas Pharma US Inc | $95 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2023 | |
| 2023-08-25 | Dexcom, Inc. | $18 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-08-24 | Corcept Therapeutics | $23 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-08-17 | Bayer Healthcare Pharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-08-16 | Astellas Pharma US Inc | $25 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2023 | |
| 2023-08-04 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 | |
| 2023-08-02 | Corcept Therapeutics | $22 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-07-19 | Corcept Therapeutics | $25 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-07-18 | IBSA Pharma Inc. | $23 | Food and Beverage | Cash or cash equivalent | LICART Drug, non-opioid analgesic | 2023 | |
| 2023-06-29 | Corcept Therapeutics | $18 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-06-16 | Astellas Pharma US Inc | $19 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2023 | |
| 2023-06-07 | Xeris Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2023 | |
| 2023-06-06 | Xeris Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2023 | |
| 2023-05-24 | SANOFI-AVENTIS U.S. LLC | $18 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-05-24 | Amryt Pharma Holdings Ltd | $15 | Food and Beverage | In-kind items and services | MYALEPT Drug, Endocrinology | 2023 | |
| 2023-05-17 | Medtronic, Inc. | $91 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2023 | |
| 2023-05-04 | SANOFI-AVENTIS U.S. LLC | $23 | Food and Beverage | In-kind items and services | TOUJEO Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-04-28 | IBSA Pharma Inc. | $24 | Food and Beverage | Cash or cash equivalent | LICART Drug, non-opioid analgesic | 2023 | |
| 2023-04-26 | Corcept Therapeutics | $20 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-04-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-04-21 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2023 | |
| 2023-04-20 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2023 | |
| 2023-04-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-03-31 | SANOFI-AVENTIS U.S. LLC | $14 | Food and Beverage | In-kind items and services | TOUJEO Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-03-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $123 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-03-22 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | SOMAVERT Drug, ENDOCRINE DISEASE;METABOLIC DISEASE | 2023 | |
| 2023-03-16 | SANOFI-AVENTIS U.S. LLC | $18 | Food and Beverage | In-kind items and services | TOUJEO Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-03-15 | Corcept Therapeutics | $21 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-02-24 | Corcept Therapeutics | $19 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2023 | |
| 2023-02-17 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2023 | |
| 2023-02-16 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-01-31 | Boehringer Ingelheim Pharmaceuticals, Inc. | $56 | Travel and Lodging | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-01-25 | SANOFI-AVENTIS U.S. LLC | $21 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-01-21 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2023 | |
| 2023-01-19 | SANOFI-AVENTIS U.S. LLC | $23 | Food and Beverage | In-kind items and services | TOUJEO Biological, Endocrine & Metabolic Diseases | 2023 | |
| 2023-01-18 | IBSA Pharma Inc. | $24 | Food and Beverage | Cash or cash equivalent | LICART Drug, non-opioid analgesic | 2023 | |
| 2022-12-29 | Lilly USA, LLC | $23 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2022 | |
| 2022-12-28 | IBSA Pharma Inc. | $23 | Food and Beverage | Cash or cash equivalent | Tirosint Drug, Endocrinology | 2022 | |
| 2022-12-13 | Dexcom, Inc. | $20 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2022 | |
| 2022-11-23 | Kowa Pharmaceuticals America, Inc. | $13 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2022 | |
| 2022-11-11 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | LEQVIO Drug, CARDIOVASCULAR | 2022 | |
| 2022-11-09 | Amgen Inc. | $100 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2022 | |
| 2022-11-09 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-10-27 | Tandem Diabetes Care, Inc. | $85 | Food and Beverage | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2022 | |
| 2022-10-20 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | BAQSIMI Drug, Diabetes | 2022 | |
| 2022-10-14 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2022 | |
| 2022-10-13 | Bayer Healthcare Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-10-12 | Radius Health, Inc. | $27 | Food and Beverage | In-kind items and services | Tymlos Biological, Endocrinology | 2022 | |
| 2022-10-10 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2022 | |
| 2022-10-06 | Xeris Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | GVOKE PFS Drug, Diabetes | 2022 | |
| 2022-09-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-09-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | $381 | Travel and Lodging | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-09-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | $121 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-09-21 | Novo Nordisk Inc | $21 | Food and Beverage | In-kind items and services | Tresiba Drug, Diabetes | 2022 | |
| 2022-09-06 | Dexcom, Inc. | $19 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2022 | |
| 2022-08-12 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-07-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-07-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,245 | Travel and Lodging | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-07-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $55 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-07-17 | Eli Lilly and Company | $11,271 | Research payment | In-kind items and services | A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 A | 2022 | |
| 2022-07-11 | Novo Nordisk Inc | $6 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-06-30 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Tresiba Drug, Diabetes | 2022 | |
| 2022-06-10 | Lilly USA, LLC | $11 | Education | In-kind items and services | 2022 | ||
| 2022-05-19 | Xeris Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | GVOKE PFS Drug, Diabetes | 2022 | |
| 2022-04-26 | Corcept Therapeutics | $94 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2022 | |
| 2022-04-12 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | SOMAVERT Drug, ENDOCRINE DISEASE;METABOLIC DISEASE | 2022 | |
| 2022-04-08 | Eli Lilly and Company | $1,289 | Research payment | In-kind items and services | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2022 | |
| 2022-04-07 | Lilly USA, LLC | $975 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2022 | |
| 2022-03-30 | RECORDATI_RARE_DISEASES_INC. | $20 | Food and Beverage | In-kind items and services | SIGNIFOR LAR Drug, ENDOCRINE AGENT | 2022 | |
| 2022-03-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $691 | Travel and Lodging | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $56 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-03-03 | Xeris Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | GVOKE PFS Drug, Diabetes | 2022 | |
| 2022-02-24 | Novo Nordisk Inc | $119 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-02-10 | Xeris Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | GVOKE PFS Drug, Diabetes | 2022 | |
| 2021-12-02 | SANOFI-AVENTIS U.S. LLC | $17 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2021 | |
| 2021-09-28 | Lilly USA, LLC | $975 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2021 | |
| 2021-08-10 | Radius Health, Inc. | $28 | Food and Beverage | In-kind items and services | Tymlos Biological, Endocrinology | 2021 | |
| 2021-08-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-08-03 | Ipsen Biopharmaceuticals, Inc | $19 | Food and Beverage | In-kind items and services | SOMATULINE DEPOT Drug, Oncology/Endocrinology | 2021 | |
| 2021-07-28 | Amarin Pharma, Inc. | $20 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,126 | Travel and Lodging | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $89 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-07-13 | Amarin Pharma, Inc. | $22 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-06-08 | Amarin Pharma, Inc. | $23 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-05-18 | Radius Health, Inc. | $22 | Food and Beverage | In-kind items and services | Tymlos Biological, Endocrinology | 2021 | |
| 2021-05-13 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-05-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-05-01 | Antares Pharma, Inc. | $13 | Food and Beverage | In-kind items and services | XYOSTED Drug, Testosterone Replacement Therapy | 2021 | |
| 2021-04-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-04-13 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2021 | |
| 2021-03-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-03-17 | Lilly USA, LLC | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2021 | |
| 2021-03-12 | SANOFI-AVENTIS U.S. LLC | $16 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrine & Metabolic Diseases | 2021 | |
| 2021-03-09 | Lilly USA, LLC | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2021 | |
| 2021-03-05 | SANOFI-AVENTIS U.S. LLC | $16 | Food and Beverage | In-kind items and services | TOUJEO Biological, Endocrine & Metabolic Diseases | 2021 | |
| 2021-02-25 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-02-16 | Lilly USA, LLC | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2021 | |
| 2021-01-29 | Eli Lilly and Company | $48 | Research payment | In-kind items and services | A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS | 2021 | |
| 2020-12-16 | Amgen Inc. | $0 | Education | In-kind items and services | 2020 | ||
| 2020-12-02 | Amgen Inc. | $0 | Education | In-kind items and services | 2020 | ||
| 2020-10-08 | Eli Lilly and Company | $1,092 | Research payment | In-kind items and services | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2020 | |
| 2020-09-22 | Lilly USA, LLC | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2020 | |
| 2020-09-03 | Novo Nordisk Inc | $4 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-08-28 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-08-28 | Novo Nordisk Inc | $11 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-07-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2020 |
The latest 200 records of 455.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | ATLAS INTERMEDIATE | $5,587 | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and sa | 2025 |
| 2025-12-05 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $13,789 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-11-05 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $12,509 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-10-24 | Amgen Inc. | ATLAS INTERMEDIATE LLC SUNCOAST CLINICAL RESEARCH LLC | $21,662 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiov | 2025 |
| 2025-10-21 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $405 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-10-09 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $7,935 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-09-24 | Amgen Inc. | SUNCOAST CLINICAL RESEARCH INC | $1,653 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiov | 2025 |
| 2025-09-04 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $14,535 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-08-06 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $6,588 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-07-02 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $3,922 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-06-03 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $15,556 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-05-20 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $202 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-05-20 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $1,113 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-05-07 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $2,775 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-04-24 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $4,500 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-04-24 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $600 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-04-16 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $600 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-04-09 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $600 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-04-03 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $9,776 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-03-18 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $4,943 | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of | 2025 |
| 2025-02-06 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $2,546 | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of | 2025 |
| 2024-12-31 | ABBVIE INC. | SUNCOAST CLINICAL RESEARCH INC | $4,624 | M21-341 ATH Ph 2b Armour Thyroid vs Synthetic T4 (ATH-MD-01) (3014-301-002) | 2024 |
| 2024-12-30 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $11,962 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-12-05 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $4,873 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-11-07 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $5,719 | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-10-03 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $16,411 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-09-04 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $23,889 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-08-02 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $9,140 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-06-06 | ABBVIE INC. | ATLAS INTERMEDIATE LLC | $16,000 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-01-09 | Eli Lilly and Company | MARIN ENDOCRINE CARE AND RESEARCH | $338 | A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 A | 2024 |
| 2024-01-02 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $15,723 | A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 A | 2024 |
| 2023-05-08 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $244,931 | A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A | 2023 |
| 2023-04-10 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $11,357 | A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A | 2023 |
| 2023-02-06 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $2,200 | A RANDOMIZED PHASE 3 OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LIS | 2023 |
| 2023-01-23 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $3,000 | A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | 2023 |
| 2023-01-10 | Eli Lilly and Company | MARIN ENDOCRINE CARE AND RESEARCH | $8,786 | A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A | 2023 |
| 2022-08-05 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $8,412 | A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 A | 2022 |
| 2022-06-22 | Eli Lilly and Company | MARIN ENDOCRINE CARE AND RESEARCH | $1,854 | A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 A | 2022 |
| 2022-03-28 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $6,750 | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2022 |
| 2022-03-28 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $5,200 | A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | 2022 |
| 2022-01-31 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $1,040 | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2022 |
| 2022-01-26 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $116 | A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | 2022 |
| 2022-01-25 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $32,048 | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2022 |
| 2022-01-11 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $297 | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2022 |
| 2021-11-26 | Welch Allyn | SUNCOAST CLINICAL RESEARCH | $19,508 | AutoDx-DR Prospective Clinical Validation Study Protocol | 2021 |
| 2021-11-26 | Welch Allyn | SUNCOAST CLINICAL RESEARCH | $550 | AutoDx-DR Prospective Clinical Validation Study Protocol | 2021 |
| 2021-10-08 | Welch Allyn | SUNCOAST CLINICAL RESEARCH | $3,850 | AutoDx-DR Prospective Clinical Validation Study Protocol | 2021 |
| 2021-10-01 | Welch Allyn | SUNCOAST CLINICAL RESEARCH | $39,937 | AutoDx-DR Prospective Clinical Validation Study Protocol | 2021 |
| 2021-10-01 | Welch Allyn | SUNCOAST CLINICAL RESEARCH | $39,937 | AutoDx-DR Prospective Clinical Validation Study Protocol | 2021 |
| 2021-05-31 | Eli Lilly and Company | San Miguel Medical | $48 | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2021 |
| 2021-05-10 | Eli Lilly and Company | MILLENNIUM RESEARCH LLC | $132 | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2021 |
| 2021-05-10 | Eli Lilly and Company | ANDROSCOGGIN CARDIO ASSOC DBA MAINE RSRH ASSOC | $202 | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2021 |
| 2021-05-10 | Eli Lilly and Company | NEW HORIZON RESEARCH CENTER | $38 | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2021 |
| 2021-05-10 | Eli Lilly and Company | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | $22 | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2021 |
| 2021-04-30 | Eli Lilly and Company | Emanuelli Research and Development Center, LLC | $48 | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2021 |
| 2021-04-13 | Eli Lilly and Company | DALLAS DIABETES AND ENDO RESEARCH CENTER PA | $3,112 | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2021 |
| 2021-04-08 | Eli Lilly and Company | GCM MEDICAL GROUP PSC | $47 | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2021 |
| 2021-04-08 | Eli Lilly and Company | CLINICAL RESEARCH ADVANTAGE | $15 | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2021 |
| 2021-03-12 | Welch Allyn | SUNCOAST CLINICAL RESEARCH | $5,595 | AutoDx-DR Prospective Clinical Validation Study Protocol | 2021 |
| 2021-03-09 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $84,651 | A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | 2021 |
| 2021-02-23 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $1,088 | A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | 2021 |
| 2021-01-12 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $8,215 | A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS | 2021 |
| 2021-01-11 | Eli Lilly and Company | DANA-FARBER CANCER INSTITUTE | $464 | A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS | 2021 |
| 2021-01-11 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $10,264 | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2021 |
| 2021-01-11 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $17,544 | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2021 |
| 2021-01-05 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $173,242 | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2021 |
| 2021-01-05 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $163,801 | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2021 |
| 2020-12-22 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $23,132 | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2020 |
| 2020-10-12 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $777 | A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | 2020 |
| 2020-09-22 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $2,356 | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN L | 2020 |
| 2020-07-23 | Eli Lilly and Company | SUNCOAST RESEARCH | $217 | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2020 |
| 2020-03-27 | Eli Lilly and Company | INTEND RESEARCH LLC | $86 | A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS | 2020 |
| 2020-03-04 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $12,863 | A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 | 2020 |
| 2020-01-28 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $292 | A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | 2020 |
| 2020-01-28 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $136 | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG IN ADULTS WITH TYPE 1 DIABETES USING CONTINUOU | 2020 |
| 2020-01-21 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $16,825 | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG IN ADULTS WITH TYPE 1 DIABETES USING CONTINUOU | 2020 |
| 2020-01-21 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $144,143 | A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS | 2020 |
| 2020-01-13 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $12,635 | A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | 2020 |
| 2020-01-09 | Eli Lilly and Company | Dana-Farber Cancer Institute | $3,362 | A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS | 2020 |
| 2020-01-08 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $6,094 | A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS | 2020 |
| 2019-09-17 | SANOFI US SERVICES INC. | SUNCOAST CLINICAL RESEARCH INC | $1,060 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of | 2019 |
| 2019-09-10 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $26,338 | A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS | 2019 |
| 2019-09-03 | SANOFI US SERVICES INC. | SUNCOAST CLINICAL RESEARCH INC | $2,473 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of | 2019 |
| 2019-08-06 | Eli Lilly and Company | Dana-Farber Cancer Institute | $2,041 | A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS | 2019 |
| 2019-08-02 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $5,131 | A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS | 2019 |
| 2019-07-16 | Eli Lilly and Company | Dana-Farber Cancer Institute | $11,581 | A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | 2019 |
| 2019-07-10 | Eli Lilly and Company | Dana-Farber Cancer Institute | $3,141 | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG IN ADULTS WITH TYPE 1 DIABETES USING CONTINUOU | 2019 |
| 2019-04-16 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $190,379 | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG IN ADULTS WITH TYPE 1 DIABETES USING CONTINUOU | 2019 |
| 2019-02-19 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $4,000 | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARG | 2019 |
| 2019-02-12 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $6,807 | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY90001 | 2019 |
| 2019-02-05 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $258,804 | A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | 2019 |
| 2019-02-04 | SANOFI US SERVICES INC. | SUNCOAST CLINICAL RESEARCH INC | $6,686 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of | 2019 |
| 2019-01-28 | Eli Lilly and Company | KENTUCKY DIABETES ENDOCRINOLOGY CENTER | $267 | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY90001 | 2019 |
| 2019-01-28 | Eli Lilly and Company | MARIN ENDOCRINE CARE AND RESEARCH | $3,834 | A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | 2019 |
| 2019-01-22 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $39,697 | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG IN ADULTS WITH TYPE 1 DIABETES USING CONTINUOU | 2019 |
| 2019-01-16 | Eli Lilly and Company | SUNCOAST CLINICAL RESEARCH | $47,952 | A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Hudson, FL, county Pasco County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) Hudson, FL | County Pasco County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 11,254 | 611,444 | 22,416,077 |
| Population, 2020 census P1 | 12,944 | 561,891 | 21,538,187 |
| Median age B01002 | 63.8 | 43.4 | 42.6 |
| Under 18 B01001 | 8.9% | 20.2% | 19.5% |
| 65 and over B01001 | 46.4% | 21.9% | 21.3% |
| Households B11001 | 5,571 | 236,163 | 8,752,810 |
| Foreign born B05002 | 8.6% | 12.3% | 21.9% |
| Median household income B19013 | $51,513 | $70,492 | $74,568 |
| Median family income B19113 | $73,393 | $89,308 | $89,891 |
| Per capita income B19301 | $36,304 | $38,864 | $42,609 |
| Poverty rate B17001 | 13.0% | 11.1% | 12.6% |
| Unemployment rate B23025 | 4.6% | 4.9% | 4.8% |
| Civilian labor force B23025 | 3,754 | 289,118 | 11,016,578 |
| Mean commute (minutes) B08013 | 34.7 | 31.1 | 28.0 |
| Bachelor's degree or higher B15003 | 18.0% | 29.2% | 34.1% |
| Housing units B25001 | 7,602 | 271,844 | 10,256,470 |
| Owner-occupied B25003 | 77.1% | 75.7% | 67.6% |
| Renters B25003 | 22.9% | 24.3% | 32.4% |
| Median home value B25077 | $269,200 | $300,900 | $359,000 |
| Median gross rent B25064 | $1,044 | $1,505 | $1,669 |
| White, not Hispanic B03002 | 85.6% | 67.5% | 50.4% |
| Black B03002 | 1.6% | 6.0% | 14.6% |
| Hispanic or Latino B03002 | 7.2% | 18.6% | 27.4% |
| Asian B03002 | 1.2% | 3.4% | 2.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Hudson, FL.
Comments